• <td id="wjkko"></td>
    <code id="wjkko"><ol id="wjkko"></ol></code>
    <pre id="wjkko"><ruby id="wjkko"><menu id="wjkko"></menu></ruby></pre>
    <table id="wjkko"></table><track id="wjkko"><ruby id="wjkko"></ruby></track>

    <td id="wjkko"><ruby id="wjkko"></ruby></td>

          1. Diagnostic Substance Manufacturing Industry Profile

            Report Page Length: 10-12
            Last Quarterly Update: 7/13/2020
            SIC Codes: 2835
            NAICS Codes: 325413
            Chapters Include:
            Industry Overview Trends & Challenges Industry Forecast
            Quarterly Industry Update Call Prep Questions Website & Media Links
            Business Challenges Financial Information Glossary & Acronyms
            View Full Sample Add To Cart

            Excerpt from Diagnostic Substance Manufacturing Industry Profile

            Companies in this industry develop and manufacture biological, chemical, and radioactive substances used in the process of detecting, diagnosing, and monitoring health conditions. Major companies include Beckman Coulter and Bio-Rad Laboratories (both based in the US), as well as bioMerieux and Guerbet (both in France) and the diagnostic divisions of major pharmaceutical companies such as Abbott (US), Roche (Switzerland), and Siemens (Germany).

            The global market for in vitro diagnostics, which includes drugs and devices, is forecast to grow from $68 billion in 2018 to $107 billion in 2027, according to MarketsandMarkets. Growth is strongest in developing nations with growing economies and rising middle-class populations.

            The US diagnostic substances industry includes about 250 establishments (single-location companies and units of multi-location companies) with combined annual revenue of about $16 billion.

            Companies that make diagnostic equipment such as x-ray machines are covered in a separate profile.

            COMPETITIVE LANDSCAPE

            Demand for diagnostics is driven by the desire to detect and treat illness and disease. The profitability of individual companies depends on their ability to promote easy-to-use, effective tests and to develop new tests. Growth is fueled by increasing rates of chronic and infectious diseases. Large companies have economies of scale in research, manufacturing, and marketing. Smaller companies can compete effectively by specializing in certain types of tests or disease targets, or through advanced product development efforts. The US industry is highly concentrated: the top eight ...

             
            View Full Sample Add To Cart Return to the Industry Profile Menu

            Related Profiles

            Here are a few profiles related to Diagnostic Substance Manufacturing that you also might be interested in viewing:

            Would you or your company benefit from having unlimited access to First Research's industry intelligence tools?

            Learn More About Subscription Options
             
            韩国电影-韩国三级-韩国r级电影-韩国理论片在线-天天影视网 <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>